ADCT ADC Therapeutics
- 4.520
- +0.110+2.49%
ADC Therapeutics News
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlook
ADC Therapeutics Price Target Cut to $8.00/Share From $9.00 by HC Wainwright & Co.
ADC Therapeutics Price Target Cut to $8.00/Share From $9.00 by HC Wainwright & Co.
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $9 to $8.
ADC Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 79.78% HC Wainwright & Co. $9 → $8 Maintains Buy 04/15/2024 102.25% HC Wainwright & Co. → $9 Re
ADC Therapeutics Ltd's Business At Risk: The Perils of Limited Control in Clinical Trials
Earnings Call Summary | ADC Therapeutics(ADCT.US) Q1 2024 Earnings Conference
The following is a summary of the ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript:Financial Performance:ADC Therapeutics SA reported Q1 2024 revenue of $17.8 million, a 7% sequential incre
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% higher in Monday's premarket activity, as investors hope for the
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday.Shares of BioNTech SE (NASDAQ:BNTX) fell sharply in today's pre-market trading following weaker-than
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of
ADC Therapeutics | 10-Q: Quarterly report
ADC Therapeutics Reveals Encouraging Phase 2 Trial Outcomes
ADC Therapeutics (ADCT.US): The 2024 Q1 financial report achieved revenue of US$18.053 million, with a previous value of US$18.992 million, with an expected value of US$18.21 million; earnings per share of -0.38 dollars, previous value of -0.53 dollars, a
ADC Therapeutics (ADCT.US): The 2024 Q1 financial report achieved revenue of US$18.053 million, with a previous value of US$18.992 million, with an expected value of US$18.21 million; earnings per share of -0.38 dollars, previous value of -0.53 dollars, and expected value of -0.56 dollars.
ADC Therapeutics Currently Expects Its Cash Runway To Extend Into Q4 Of 2025
ADC Therapeutics Currently Expects Its Cash Runway To Extend Into Q4 Of 2025
ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.56) by 32.14 percent. The company reported quarterly sales of $18.053 mill
ADC Therapeutics 1Q Loss $46.6M >ADCT
ADC Therapeutics 1Q Loss $46.6M >ADCT
ADC Therapeutics 1Q Loss/Shr 56c >ADCT
ADC Therapeutics 1Q Loss/Shr 56c >ADCT
ADC Therapeutics 1Q Rev $18.1M >ADCT
ADC Therapeutics 1Q Rev $18.1M >ADCT
Analysis
Price Target
No Data
